Retatrutide Weight Loss Results: What Clinical Trials Show

In the Phase 2 clinical trial published in The New England Journal of Medicine, retatrutide at the 12 mg weekly dose produced an average weight loss of 24.2% of body weight over 48 weeks. For a 250-pound person, that translates to roughly 60 pounds lost.

This result is the highest average weight loss ever recorded in a randomized controlled pharmaceutical trial. It exceeds the results of both semaglutide (approximately 15% in the STEP 1 trial over 68 weeks) and tirzepatide (approximately 22.5% in the SURMOUNT-1 trial over 72 weeks). Notably, the retatrutide result was achieved in only 48 weeks, compared to the longer durations of the semaglutide and tirzepatide trials.

The trial tested five dose levels with clearly dose-dependent weight loss:

1 mg weekly: approximately 8% of body weight lost 2 mg weekly: approximately 13% of body weight lost 4 mg weekly: approximately 17% of body weight lost 8 mg weekly: approximately 22% of body weight lost 12 mg weekly: approximately 24.2% of body weight lost

The placebo group lost approximately 2% of body weight. Every active dose group significantly outperformed placebo. Even the lowest dose (1 mg) produced weight loss comparable to some older anti-obesity medications at their maximum doses.

Putting retatrutide in context with currently approved GLP-1 medications:

Semaglutide 2.4 mg (Wegovy): approximately 15% body weight loss over 68 weeks in the STEP 1 trial. Semaglutide targets a single receptor (GLP-1).

Tirzepatide 15 mg (Zepbound): approximately 22.5% body weight loss over 72 weeks in the SURMOUNT-1 trial. Tirzepatide targets two receptors (GLP-1 + GIP).

Retatrutide 12 mg: approximately 24.2% body weight loss over 48 weeks in the Phase 2 trial. Retatrutide targets three receptors (GLP-1 + GIP + glucagon).

The trend is clear: each additional receptor target has been associated with incrementally greater weight loss. The addition of glucagon receptor agonism in retatrutide appears to provide meaningful additional benefit, likely through increased energy expenditure.

While these results are remarkable, several caveats apply. Phase 2 trials are smaller than Phase 3 pivotal trials and may not fully represent the results that will be seen in broader populations. The retatrutide Phase 2 trial enrolled approximately 340 participants, compared to thousands in the STEP and SURMOUNT programs.

Direct cross-trial comparisons have limitations. The studies used different patient populations, durations, and endpoints. A true head-to-head comparison would require a randomized trial testing retatrutide against semaglutide and tirzepatide in the same population -- such a study has not been conducted.

The 48-week duration is also shorter than the 68-72 weeks used in semaglutide and tirzepatide pivotal trials. Weight loss may have continued beyond 48 weeks with retatrutide, which would make the final numbers even more impressive, but this is speculative until longer-term data are available.

Additionally, the proportion of participants achieving specific weight loss thresholds is a meaningful metric. In the 12 mg group, a substantial majority of participants lost 15% or more of their body weight, and a significant percentage exceeded 25%. These threshold analyses are important because certain health benefits, such as diabetes remission and cardiovascular risk reduction, become more likely at higher weight loss levels.